|
||||||||||||||||||||||
|
|
Adjuvant Pazopanib in Stage I NSCLC
Basic Trial Information
Summary The aim of this study is to evaluate the efficacy and safety of pazopanib compared with placebo in patients with T < or = 5 cm, N0 (stage I according to TNM 2009) completely resected NSCLC. Further Study Information The study will be conducted in two phases as follows:
Eligibility Criteria Inclusion Criteria: 1. Complete resection of the primary tumour and local extension has to be performed. All margins must be free of microscopical disease. At the time of resection, a complete mediastinal lymph-node resection or lymph-node sampling is required. Surgeons are encouraged to dissect or sample all accessible nodal levels. 2. Single surgically resected pathological stage I NSCLC lesion: consisting of a tumor < 5 cm in greatest dimension (see TNM staging on Appendix 10). 3. No regional lymph node involvement. 4. Pre-operative petscan 5. Satisfactory healing of surgical wound. 6. Patients >= 18 and < 70 years of age. 7. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1. 8. Recruited to the study and available to start treatment investigational product at least 4 weeks but no longer that 8 weeks after the surgical resection of the NSCLC. 9. No approved or investigational anti-cancer therapy concurrently or in the 5 years prior to start of study drug, including tumor embolization, chemotherapy, radiation therapy, immunotherapy, hormone therapy, biologic therapy, or anti angiogenic therapy (e.g., inhibitors of VEGF or VEGFR). 10. Adequate organ system function 11. Ability to swallow and retain oral medication. 12. A female is eligible to enter and participate in this study if she is of: Non-childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female who has undergone:
Female patients who are lactating should discontinue nursing prior to the first dose of study drug and should refrain from nursing throughout the treatment period and for 15 days following the last dose of study drug. A male with a female partner of childbearing potential is eligible to enter and participate in the study if he uses a barrier method of contraception or abstinence during the study. 13. French Patients: in France, a patient will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security insurance. Exclusion Criteria: 1. Prior malignancy. Note: Patients who have had another malignancy and were treated more than 5 years ago and have since been considered cured, or patients with a history of basocellular skin carcinoma or in situ carcinoma of the uterine cervix are eligible. 2. Presence of any concurrent disease or condition that would make the subject inappropriate for study participation including any unresolved or unstable, serious toxicity from prior administration of another investigational drug or any serious medical disorder that would interfere with the subject's safety, obtaining informed consent, or compliance with all study related procedures. 3. Major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks prior to beginning therapy, or anticipation of the need for a major surgical procedure during the course of the study. 4. History or clinical evidence of nodal or distant metastases (screening of brain metastasis is mandatory). 5. Bronchioalveolar carcinoma of lobar or multi lobar involvement. Bronchioalveolar carcinomas presenting as a discrete solitary radiological mass or nodule are eligible. 6. History of human immunodeficiency virus infection or chronic hepatitis B or C. 7. History of hemoptysis after resection of lung cancer. 8. Clinically significant gastrointestinal abnormalities including, but not limited to:
9. Presence of active or uncontrolled infection. 10. Evidence of active bleeding or bleeding diathesis. 11. History of any one or more of the following cardiovascular conditions within the past 6 months:
12. Poorly controlled hypertension (defined as a systolic blood pressure (SBP) of >= 140 mmHg or diastolic blood pressure (DBP) >= 90 mmHg. Note: Initiation or adjustment of anti-hypertensive medication(s) is permitted prior to study entry. Blood pressure (BP) must be re-assessed on two occasions separated by at least 5 minutes. The mean SBP/DBP values from both BP assessments must be <140/90 mmHg in order for a subject to be eligible for the study. 13. Following abnomalies on ECG : Q wave, ischemia, QT > 450 msec, atrio-ventricular block 2 or 3, atrial fibrilation 14. Therapeutic anticoagulation treatment. 15. Chronic daily treatment with aspirin (≥ 325 mg/day) or non-steroidal anti-inflammatory agents known to inhibit platelet function. Treatment with dipyridamole, ticlopidine, clopidogrel and/or cilostazol is also not allowed. 16. Pregnant or lactating female. 17. Concurrent treatment with an investigational agent or participation in another clinical trial. 18. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib. Trial Lead Organizations/Sponsors French Thoracic Oncology Intergroup Center
Trial Sites
Link to the current ClinicalTrials.gov record. Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov. Back to Top |
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
A Service of the National Cancer Institute |